Obiettivo Several forms of neuroadaptation are controlled by transient increases in the nuclear calcium concentration. Nuclear calcium regulates expression of crucial genes and alterations of this signaling network likely underlie many neurological disorders. Our work led us to design two innovative strategies exploiting the therapeutic potential of nuclear calcium signaling: 1-developing direct nuclear calcium signaling activators/inhibitors (NCSA/I) and 2-manipulating expression and/or function of nuclear calcium targets. The proposed activities and budget - taking the ERC-PoC stroke study as the model project – will be used to meet the essential pre-commercial requirements prior starting up a company focusing on early drug discovery in the area of targeted nuclear calcium signaling modulation:R&D objectives: 1-PoC to validate our lead mimicking a stroke-protective regulator: VEGFD; 2-Add novel drug targets & assays and transfer to screening partner; 3-Mass screening and lead validation to expand IP;Business objectives: 1-Manage emerging IP platform; 2-Complete fund raising during ERC funding period; 3-Close early drug discovery partnership.As part of the ERC project 233024, we identified a nuclear-calcium dependent gene, VEGFD, as a new anti-stroke drug target. We showed that VEGFD regulates neuronal morphology and cognition and demonstrated that VEGFD delivery in the mouse brain prevents stroke-induced dendritic loss and promotes long-term recovery. We selected a highly biologically active VEGFD peptide mimetic (VPM) as our first lead for a conceptually novel nasal spray stroke therapy. Senior business experts advised and helped us to establish a business plan and to pre-negotiate collaborative partnerships with companies and institutions required to deliver on our objectives. Thus, by partnering with industry professionals we were able to define a clear go-to-commercialization strategy while minimizing risks originating from possible lack of business experience. Campo scientifico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencesbiological sciencesbiochemistrybiomoleculesnatural scienceschemical sciencesinorganic chemistryalkaline earth metalsmedical and health sciencesbasic medicineneurologystroke Programma(i) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Argomento(i) ERC-PoC-2014 - ERC Proof of Concept Grant Invito a presentare proposte ERC-2014-PoC Vedi altri progetti per questo bando Meccanismo di finanziamento ERC-POC - Proof of Concept Grant Istituzione ospitante RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG Contribution nette de l'UE € 147 968,00 Indirizzo SEMINARSTRASSE 2 69117 Heidelberg Germania Mostra sulla mappa Regione Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 147 968,50 Beneficiari (1) Classifica in ordine alfabetico Classifica per Contributo netto dell'UE Espandi tutto Riduci tutto RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG Germania Contribution nette de l'UE € 147 968,00 Indirizzo SEMINARSTRASSE 2 69117 Heidelberg Mostra sulla mappa Regione Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 147 968,50
